Previous 10 | Next 10 |
2023-11-25 03:20:10 ET Summary Latest revenue results are not favorable for MannKind nor United. MannKind needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. United has been an unreliable partner for future use of MannKind's technology...
2023-11-09 11:12:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re a fan of the hit TV show Shark Tank , you’ve probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not o...
2023-11-08 14:42:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In October, I warned investors that flying car firm EHang (NASDAQ: EH ) had an order book that looked suspiciously weak : During the most recent quarter, EHang delivered j...
2023-11-07 11:20:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips EHang (NASDAQ: EH ) stock is taking a plunge after Hindenburg Research published a short report on the Chinese electric vertical take-off and landing (eVTOL) company. In...
2023-11-01 14:38:07 ET United Therapeutics Corporation (UTHR) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – Head of Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer M...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
2023-11-01 06:04:01 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter...
United Therapeutics Corporation (UTHR) is expected to report $4.89 for Q3 2023
2023-11-01 04:17:37 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amid Generic Threat United Therapeutics: Fundamental, Technical Analyses Justify A Buy Decision United Therapeutics Q3 2023 Earnings Preview United Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...